Selinexor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Selinexor (Karyopharm Therapeutics/Ono Pharmaceutical) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1. XPO1 is responsible for the transport of around 220 proteins from the nucleus of the cell to the cytoplasm, including many growth regulators and tumor suppressors. By preventing the export of these proteins, they are retained in the nucleus, leading to growth inhibition. XPO1 has been shown to be crucial for multiple myeloma (MM) cell survival, and selinexor inhibits MM cell growth and induces apoptosis in vivo and in vitro. It has also been shown to overcome proteasome inhibitor resistance in cells when added to Kyprolis (carfilzomib; Amgen/Ono Pharmaceutical) or Velcade (bortezomib; Takeda/Johnson & Johnson).
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 selinexor : NHL: Diffuse large B-cell lymphoma (DLBCL)
17 selinexor : Multiple myeloma
LIST OF FIGURES
10 Figure 1: Selinexor for diffuse large B-cell lymphoma – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary for selinexor in diffuse large B-cell lymphoma
12 Figure 3: Datamonitor Healthcare’s drug assessment summary for selinexor in diffuse large B-cell lymphoma
14 Figure 4: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
23 Figure 5: Selinexor for multiple myeloma – SWOT analysis
24 Figure 6: Datamonitor Healthcare’s drug assessment summary for selinexor in multiple myeloma
25 Figure 7: Datamonitor Healthcare’s drug assessment summary for selinexor in multiple myeloma
27 Figure 8: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Selinexor drug profile
7 Table 2: Selinexor pivotal trial data in diffuse large B-cell lymphoma
15 Table 3: Selinexor sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
18 Table 4: Selinexor drug profile
19 Table 5: Selinexor Phase III trial in multiple myeloma
21 Table 6: Selinexor early-phase data in multiple myeloma
28 Table 7: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
30 Table 8: Patients treated with selinexor across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Blincyto 
Sign up to the